<unk>  (E-EPA, icosapent<unk> , sold under the brand name Vascepa among others, is a medication used to treat dyslipidemia and hypertriglyceridemia. It is used in combination with changes in diet in adults with hypertriglyceridemia ≥ 150 mg/dL. Further, it is often required to be used with a statin (maximally-tolerated dose). It is made from the omega-3 fatty acid<unk>  acid (EPA). The US Food and Drug Administration (FDA) granted the approval of icosapent<unk>  in 2012 to Amarin Corporation, and it became the second fish oil-based medication after omega-3-acid<unk>  esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels". The most common side effects are musculoskeletal pain, peripheral edema (swelling of legs and hands), atrial fibrillation, and arthralgia (joint pain). Other common side effects include bleeding, constipation, gout, and rash. It has been approved by the FDA as a generic medication.
Ethyl eicosapentaenoic acid
Ellagic acid
Fish oil 
Fish oil
Soybean oil
Etiocholanolone
Conjugated linoleic acid
Retinyl palmitate